Actinogen treats first patient in XanaMIA trial for Alzheimer’s

​Actinogen has treated the first participant in the OLE segment of its Phase IIb/III pivotal XanaMIA AD trial after completion of 36 weeks in the randomised phase.

The post Actinogen treats first patient in XanaMIA trial for Alzheimer’s appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.